Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0OZ8W
|
|||
| Drug Name |
Biphenyl derivative 1
|
|||
| Synonyms |
PMID29473428-Compound-55
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
BRISTOL-MYERS SQUIBB COMPANY
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C31H38N6O
|
|||
| Canonical SMILES |
CCC(CC)N(CC(C)C)C1=C(C=C(C=C1)C2=CC=CC=C2C3=NNN=N3)NC(=O)CC4=CC=C(C=C4)C
|
|||
| InChI |
1S/C31H38N6O/c1-6-25(7-2)37(20-21(3)4)29-17-16-24(26-10-8-9-11-27(26)31-33-35-36-34-31)19-28(29)32-30(38)18-23-14-12-22(5)13-15-23/h8-17,19,21,25H,6-7,18,20H2,1-5H3,(H,32,38)(H,33,34,35,36)
|
|||
| InChIKey |
CERFYCIXDOVMJH-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Indoleamine 2,3-dioxygenase 1 (IDO1) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Indoleamine 2,3-dioxygenase 1 (IDO1) | Target's Patent Info | [1] | |
| BioCyc | Superpathway of tryptophan utilization | |||
| Tryptophan degradation | ||||
| L-kynurenine degradation | ||||
| Tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde | ||||
| NAD de novo biosynthesis | ||||
| KEGG Pathway | Tryptophan metabolism | |||
| Metabolic pathways | ||||
| African trypanosomiasis | ||||
| NetPath Pathway | TSLP Signaling Pathway | |||
| IL5 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathwhiz Pathway | Tryptophan Metabolism | |||
| Reactome | Tryptophan catabolism | |||
| WikiPathways | Tryptophan metabolism | |||
| Metabolism of amino acids and derivatives | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.